Back to Search
Start Over
PepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1
- Source :
- GlobeNewswire. February 20, 2024
- Publication Year :
- 2024
-
Abstract
- BOSTON, Feb. 20, 2024 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- GlobeNewswire
- Publication Type :
- News
- Accession number :
- edsgcl.783058935